|MDACC Study No:||2011-0374 (clinicaltrials.gov NCT No: NCT01430351)|
|Title:||A Phase I Lead-in to a 2x2x2 Factorial Trial of Temozolomide, Memantine, Mefloquine, and Metformin as Post-Radiation Adjuvant Therapy of Glioblastoma Multiforme|
|Principal Investigator:||Marta Penas-Prado|
|Treatment Agent:||Mefloquine; Memantine; Metformin; Temozolomide|
|Study Description:||The goal of this clinical research study is to find the highest tolerable dose |
of temozolomide in combination with memantine, mefloquine, and/or metformin
that can be given to patients with glioblastoma who have already been given
radiation and chemotherapy in combination. The safety of these drug
combinations will also be studied.
Temozolomide is designed to kill cancer cells by damaging DNA (the genetic
material of cells). The damaged DNA may cause tumor cell death.
Memantine is designed to block the activity of a protein found on the surface
of cells that may control tumor growth and survival. This may stop further
spread of tumor cells.
Mefloquine is designed to block a protein that helps to clean the waste in the
cells and to destabilize the cell membrane. Blocking this protein may cause
tumor cell death.
Metformin is designed to block a protein in tumor cells that is important in
tumor growth and blood vessel development. This may cause cell death or reduce
the spread of the disease.